← Eichor
Study identifier: NCT07189936 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

Condition: Post-Acute COVID-19 Syndrome · Postural Tachycardia Syndrome (POTS) · SARS CoV 2 Infection  ·  Sponsor: Vanderbilt University Medical Center

PhasePhase 2
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo

This description comes directly from the study's public registry record.

Talk to the study team

Marwa Mohamed, PhD  ·  6159702384  ·  marwa.mohamed@vumc.org

Cyndya Shibao, MD  ·  (615)936-4584  ·  Cyndya.shibao@vumc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Cyndya ShibaoNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07189936